News & Updates

Show Multimedia Only
New paradigm in obesity diagnosis & Tx: Look beyond BMI, treat to target to reduce complications
New paradigm in obesity diagnosis & Tx: Look beyond BMI, treat to target to reduce complications
02 Dec 2025 byChristina Lau

Obesity diagnosis should be based beyond BMI alone and include assessment of excess adiposity, organ dysfunction, daily activity limitations, and obesity-related diseases. A treat-to-target approach should be adopted to achieve disease-modifying effects and reduce obesity-related complications, according to Dr Samantha Hocking of the University of Sydney, Australia, who spoke at the 8th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).

New paradigm in obesity diagnosis & Tx: Look beyond BMI, treat to target to reduce complications
02 Dec 2025
Osimertinib linked to cardiac events in NSCLC patients
Osimertinib linked to cardiac events in NSCLC patients
26 Nov 2025 byStephen Padilla

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.

Osimertinib linked to cardiac events in NSCLC patients
26 Nov 2025